Stocks To Watch: Cisco Systems, Inc. (NASDAQ:CSCO), L Brands Inc (NYSE:LB), GlycoMimetics Inc (NASDAQ:GLYC) And Synopsys, Inc. (NASDAQ:SNPS)

Stocks To Watch: Cisco Systems, Inc. (NASDAQ:CSCO), L Brands Inc (NYSE:LB), GlycoMimetics Inc (NASDAQ:GLYC) And Synopsys, Inc. (NASDAQ:SNPS)

0
355
The Street Isn’t Happy With Cisco’s Guidance

At least four companies’ shares are worth watching on Thursday. They are: Cisco Systems, Inc. (NASDAQ:CSCO), L Brands Inc (NYSE:LB), GlycoMimetics Inc (NASDAQ:GLYC) and Synopsys, Inc. (NASDAQ:SNPS).

  • Cisco Systems, Inc. (NASDAQ:CSCO) delivered earnings of 60 cents a share for the third quarter exceeding expectations of 58 cents a share. Similarly, its revenue of $11.94 billion came in above the estimates of $11.89 billion. Moving ahead, the company guided its adjusted EPS between 60 and 62 cents a share on estimated revenue fall of 6 – 4 percent in the fourth quarter. This is lower than the Street predictions of an EPS of 62 cents and a revenue drop of about one percent. Following the downbeat forecast, the stock suffered 7.72 percent fall in the after-hours trading on Wednesday.
  • L Brands Inc (NYSE:LB) reported earnings of 33 cents a share for the first quarter that is ahead of the Street analysts’ consensus of 29 cents. However, its revenue of $2.44 billion, which dipped 6.5 percent from the year-ago period, came in line with the estimates. Going forward, the company lifted its full year EPS forecast to $3.10 – $3.40 from $3.05 – $3.35 projected earlier. For the second quarter, the company sees its EPS 40 – 45 cents. Analysts are looking for an EPS of 46 cents for the second quarter and $3.21 for the full year. Following the upbeat guidance, the stock jumped 6.82 percent in the extended hours trading on Wednesday.
  • GlycoMimetics Inc (NASDAQ:GLYC) shares have jumped 37.6 percent in after-hours trading on Wednesday after the company disclosed that FDA has granted its GMI-1271 a breakthrough therapy designation. The drug candidate is meant for treating adult relapsed/refractory acute myeloid leukemia (AML). The company thinks that the drug has the potential to address unmet therapeutic requirements when combined with chemotherapy for patients with AML. The company is encouraged with its clinical trials until now.
  • Synopsys, Inc. (NASDAQ:SNPS) delivered earnings of 88 cents a on revenue of $680.1 million share for the second quarter. This is better than the Street estimates of 86 cents a share and revenue of $672.4 million. Moving ahead, the company sees its adjusted EPS to be 91 – 94 cents on revenue of $685 – $700 million for the third quarter. For the full year, the company looks at achieve an EPS of $3.24 – $3.29 and revenue of $2.65 – $2.67 billion. Analysts are looking for an EPS of 73 cents and $637.5 million for third quarter and $3.25 and $2.6 billion revenue for the full year. Following this, the stock advanced 2.31 percent in after-hours trading on Wednesday.